Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Lichtenstein

Gastroenterology Philadelphia, PA Medical Doctor

NPI 1861479594 CMS profile 220764

3401 N Broad St, Fl 6, Philadelphia, PA 19140

Open in the dashboard

General payments

$191,803

211 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Lichtenstein of Philadelphia, PA is reported in the CMS Open Payments database as having received $191,803 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,480 17
2024 General $28,869 25
2023 General $9,629 14
2022 General $39,937 72
2021 General $26,502 26
2020 General $12,805 8
2019 General $43,581 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Lichtenstein
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Lichtenstein were reported at $30,480. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Lichtenstein Gastroenterology median Middle half National median
2019 $43,581 $417 $126–$1,100 $163
2020 $12,805 $224 $74–$624 $114
2021 $26,502 $352 $106–$1,054 $132
2022 $39,937 $448 $129–$1,270 $149
2023 $9,629 $533 $150–$1,390 $160
2024 $28,869 $605 $160–$1,606 $164
2025 $30,480 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Olympus Corporation of the Americas $78,718 110 payments
  2. Boston Scientific Corporation $65,751 67 payments
  3. Teleflex LLC $10,563 1 payment
  4. Palette Life Sciences, Inc. $10,175 3 payments
  5. Gyrus ACMI, Inc. $7,336 8 payments
  6. Ambu A/S $6,587 3 payments
  7. Olympus Corporation $2,915 6 payments
  8. Augmenix, Inc. $2,800 2 payments
  9. Olympus America Inc. $2,585 3 payments
  10. Olympus Medical Systems Corporation $1,565 2 payments
  11. Other $2,809 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $113,513 66 payments
  2. Education $55,900 31 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,105 13 payments
  4. Travel and Lodging $5,280 50 payments
  5. Food and Beverage $3,005 51 payments
Products named General payments · program years 2019–2025
  1. Olympus Hemostasis Devices $29,475 31 payments
  2. Olympus EMR & ESD Devices $29,075 29 payments
  3. Olympus EUS Devices $29,075 29 payments
  4. HANAROSTENT Esophagus TTS(CCC) $15,156 9 payments
  5. Olympus EndoTherapy Accessories $14,924 10 payments
  6. Olympus GI Accessories $14,151 19 payments
  7. VISIGLIDE $13,670 23 payments
  8. Single Use Electrosurgical Knife KD-655 $12,484 23 payments
  9. DISPOSABLE DISTAL ATTACHMENT $12,329 32 payments
  10. Clinical Trial Product $12,250 4 payments
  11. Other $115,384 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

95

Median for Gastroenterology: 569

Drug cost

$5,383

Median for Gastroenterology: $104,976

Branded share of claims

82.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mesalamine Generic 17 $4,011
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 49 $857
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 29 $515

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$27,418

Medicare's payments for the services billed

Medicare patients

128

Average age 72

Services billed

221

64 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Heart failure 34%
Chronic kidney disease 34%
Arthritis 34%
Ischemic heart disease 33%
Depression 30%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record